Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma.

Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma.

Publication date: May 12, 2019

To assess the efficacy of intravitreal aflibercept in patients suffering from post-radiation macular edema following plaque radiotherapy for choroidal melanoma.

This prospective, interventional case series included patients affected by radiation maculopathy (RM) with macular edema secondary to ruthenium-106 plaque brachytherapy for choroidal melanoma. The effect of intravitreal aflibercept on best-corrected visual acuity (BCVA), central foveal thickness (CFT) detected by spectral domain optical coherence tomography (sd-OCT), and Horgan’s grading scale of RM was evaluated throughout the 24-month follow-up. Intraocular pressure (IOP) and possible complications were also recorded.

Nine eyes of 9 patients were included. A mean of 4.4 +/- 1.2 injections were given over the 24 months. At the end of follow-up, mean BCVA was significantly improved, from 0.9 +/- 0.19 logMAR at baseline to 0.56 +/- 0.3 logMAR (P = 0.028), and mean CFT was significantly decreased, from 546 +/- 123 μm at baseline to 223 +/- 34 μm (P 

Fallico, M., Reibaldi, M., Avitabile, T., Longo, A., , Bonfiglio, Chronopoulos, A., Caltabiano, R., Spatola, C., and Russo, A. Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma. 22600. 2019 Graefes Arch Clin Exp Ophthalmol.

Concepts Keywords
Brachytherapy Radiation
Choroidal Melanoma Tomography
Foveal Brachytherapy
Intraocular Pressure Maculopathy
Macular Edema Intravitreal administration
Optical Coherence Tomography Aflibercept
Radiation Uveal melanoma
Ruthenium Macular edema
Visual Acuity Cancer treatments
Breakthrough therapy
Medical physics
Health
Clinical medicine
Medicine
Radiotherapy
Brachytherapy
Radiation

Semantics

Type Source Name
disease MESH complications
gene UNIPROT PLXNA2
disease MESH visual
gene UNIPROT BEST1
gene UNIPROT SLC35G1
disease MESH suffering
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
disease DOID macular edema
disease MESH macular edema
drug DRUGBANK Aflibercept

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *